KEAP1 and COVID-19: This may be related to the fact that the Nrf2 inhibitor complex, i.e., Keap1/Cul3, can direct IκBα to ubiquitination and degradation [41], and in patients who did not survive COVID-19, the level of Keap1 showed a downward trend.